(Q61756898)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Francesco Cappello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Ignazio Barbagallo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Andrea Mangiameli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Giovanni Li Volti

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Federico Salamone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

2 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

477-486

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Treating fatty liver for the prevention of cardiovascular diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Histopathology of non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Fatty liver and lipotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Scavenging of reactive oxygen species by silibinin dihemisuccinate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Antioxidant activity of silybin in vivo during long-term iron overload in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Silibinin protects mice from T cell-dependent liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Purification and properties of acyl-CoA oxidase from rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Extraction of tissue long-chain acyl-CoA esters and measurement by reverse-phase high-performance liquid chromatography.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

The role of oxidative stress in non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Peroxynitrite detoxification and its biologic implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Redox regulation of nuclear post-translational modifications during NF-kappaB activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Liver NF-kappaB and AP-1 DNA binding in obese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

iNOS-mediated nitric oxide production and its regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2011.12.003

10.1016/J.TRSL.2011.12.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22633099%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference